John M Koomen
Overview
Explore the profile of John M Koomen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
3632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freeman C, Noble J, Menges M, Villanueva R, Nakashima J, Figura N, et al.
Blood
. 2024 Dec;
PMID: 39652773
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver and alternative options are...
2.
Lodovichi S, Nepomuceno T, Woods N, Rix U, Koomen J, Pellicioli A, et al.
iScience
. 2024 Nov;
27(11):111252.
PMID: 39569366
PARP1 inhibitors (PARPis) are used for treatment of cancers with mutations in or that are deficient in homologous recombination. The identification of modulators of PARP1 activity is critical to understand...
3.
Ozakinci H, Alontaga A, Cano P, Koomen J, Perez B, Beg A, et al.
JTO Clin Res Rep
. 2024 Oct;
5(11):100723.
PMID: 39386315
Introduction: The translation of gene expression profiles of SCLC to clinical testing remains relatively unexplored. In this study, gene expression variations in SCLC were evaluated to identify potential biomarkers. Methods:...
4.
Sukka S, Ampomah P, Darville L, Ngai D, Wang X, Kuriakose G, et al.
Nat Metab
. 2024 Sep;
6(11):2204.
PMID: 39285251
No abstract available.
5.
Hu Q, Remsing Rix L, Desai B, Miroshnychenko D, Li X, Welsh E, et al.
bioRxiv
. 2024 Sep;
PMID: 39253447
Cancer-associated fibroblasts (CAFs) are associated with tumor progression and modulate drug sensitivity of cancer cells. However, the underlying mechanisms are often incompletely understood and crosstalk between tumor cells and CAFs...
6.
Sukka S, Ampomah P, Darville L, Ngai D, Wang X, Kuriakose G, et al.
Nat Metab
. 2024 Sep;
6(9):1736-1755.
PMID: 39242914
Macrophage efferocytosis prevents apoptotic cell (AC) accumulation and triggers inflammation-resolution pathways. The mechanisms linking efferocytosis to resolution often involve changes in macrophage metabolism, but many gaps remain in our understanding...
7.
Guergues J, Wohlfahrt J, Koomen J, Krieger J, Varma S, Stevens Jr S
Proteomics
. 2024 Sep;
25(3):e2400129.
PMID: 39235396
Targeted proteomics, which includes parallel reaction monitoring (PRM), is typically utilized for more precise detection and quantitation of key proteins and/or pathways derived from complex discovery proteomics datasets. Initial discovery-based...
8.
Di Meo F, Kale B, Koomen J, Perna F
Mol Ther
. 2024 Jul;
32(9):2892-2904.
PMID: 39068512
Immune-based therapeutic interventions recognizing proteins localized on the cell surface of cancer cells are emerging as a promising cancer treatment. Antibody-based therapies and engineered T cells are now approved by...
9.
Darville L, Lockhart J, Reddy S, Fang B, Izumi V, Boyle T, et al.
Methods Mol Biol
. 2024 Jul;
2823:193-223.
PMID: 39052222
Archived tumor specimens are routinely preserved by formalin fixation and paraffin embedding. Despite the conventional wisdom that proteomics might be ineffective due to the cross-linking and pre-analytical variables, these samples...
10.
Chouhan S, Sridaran D, Weimholt C, Luo J, Li T, Hodgson M, et al.
Nat Commun
. 2024 Jul;
15(1):5629.
PMID: 38965223
Mutations that decrease or increase the activity of the tyrosine phosphatase, SHP2 (encoded by PTPN11), promotes developmental disorders and several malignancies by varying phosphatase activity. We uncovered that SHP2 is...